StockDriftsStockDriftsTop 3 Dc Funds LP Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| TCRX | TSCAN THERAPEUTICS INC | 49.27% | 630.0K | $617K | +0.00%(+0) | $8.34(-90.74%) | 2026-06-30 | |
| BRNS | BARINTHUS BIOTHERAPEUTICS PL | 33.82% | 642.2K | $424K | +0.00%(+0) | $16.78(-96.66%) | 2026-06-30 | |
| HOWL | WEREWOLF THERAPEUTICS INC | 16.92% | 589.1K | $212K | +0.00%(+0) | $17.31(-97.72%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | -35.61% | -73.31% | -45.68% | -95.27% |
| Top 20 Holdings Unweighted | -28.59% | -63.59% | -40.70% | -92.67% |
Dc Funds LP reports $1.25M in US-listed equity holdings across 3 positions in its most recent 13F filing. Its largest disclosed positions are TCRX (49.3%), BRNS (33.8%) and HOWL (16.9%). The top 20 holdings account for 100.01% of reported assets. Its disclosed equity book has returned -73.31% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.
Sign up free to track Dc Funds LP, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Dc Funds LP’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1869028). View Dc Funds LP’s 13F filings on SEC